RedHill Biopharma Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.8M
- Price
- $0.625
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.47%
- Volume
- 15.3K
About
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Quick stats
Shares outstanding6.1M
Computed float2.3M
Float / shares37.5%
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001553846
Websitehttps://www.redhillbio.com
AI Summary
AI-generated1/9
standardbullishoperations update
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
RedHill is advancing discussions for its investigational drug opaganib as a potential treatment for the Ebola outbreak, which has now reached 3,221 confirmed cases and 1,407 deaths. The company is coordinating with African health agencies and universities to evaluate the oral drug, which has shown preclinical synergy with Gilead's remdesivir.
Data from a Phase 3 COVID-19 study supports opaganib's use, showing a 70.2% reduction in mortality when used as an add-on to standard care and improving viral RNA clearance times by at least four days. RedHill also noted prior selection of opaganib by U.S. BARDA for Ebola development, boosting confidence in its dual mechanism of action against the virus.
Despite the positive data, the company emphasized that opaganib is an investigational drug not yet approved by any regulatory authority and remains dependent on successful partnership discussions.
Red flags
- Opaganib is an investigational new drug and has not been approved by any regulatory authority
- Partnership discussions are ongoing and not finalized
- Prior animal studies showed mixed results across two models